MADRID and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: 9th Sachs Annual Neuroscience Innovation Forum, January 11Location: Marines’ Memorial Club, San Francisco, USAPresentation type: Company presentationPresentation time: 10:35 am (PST) 44th Annual J.P. Morgan Healthcare Conference, J ...

Industry Overview - Genomics is a comprehensive study of genomes, which has gained significant interest from pharmaceutical and biotechnology companies for understanding diseases and developing therapies [2] - The distinction between genetics and genomics is crucial, with genomics focusing on the complete set of genes and their interactions within an organism [3] - Insights from genomic research are increasingly utilized to evaluate patient responses to drugs and support the development of targeted therapies, advancing personalized medicine [4] - The growth of genomics has also bolstered synthetic biology, which applies engineering principles to biology for various applications, including drug discovery and gene editing [5] - The rapid advancements in genomics are driven by significant reductions in the cost and time required for genome sequencing [6] Market Projections - The genomics market is projected to reach $80.17 billion by 2032 [9] - The global synthetic biology market was valued at $18.94 billion in 2025 and is expected to grow at a CAGR of 17.7% from 2026 to 2033 [9] Key Companies - **Pacific Biosciences of California (PACB)**: Specializes in advanced long-read sequencing systems for various applications, including healthcare and agriculture. The company has a Zacks Rank 2 (Buy) [12][14] - **Wave Life Sciences (WVE)**: A clinical-stage biotechnology company focusing on RNA medicines. The company reported positive interim data for its obesity treatment candidate WVE-007, which showed improvements in body composition [15][17] - **Sana Biotechnology (SANA)**: Developing cell engineering platforms for diseases like type 1 diabetes and B-cell cancers. The company has suspended its CAR T programs to focus on more promising candidates and has a Zacks Rank 3 [19][21]

Core Insights - Biomerica, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has set a national Medicare payment rate of $300 for its inFoods® IBS test, effective January 1, 2026, under the Clinical Laboratory Fee Schedule (CLFS) [1][9] - The establishment of a dedicated CPT® Proprietary Laboratory Analyses (PLA) code for inFoods® IBS, effective October 1, 2025, enhances the test's market position and patient access [2] Commercial Milestone - The $300 payment rate from CMS provides a foundation for negotiations with private insurers, as CMS is the largest payer in the U.S. healthcare system, accounting for approximately 21% of total healthcare expenditure [3][9] - The CEO of Biomerica emphasized that the pricing determination is a significant milestone for both the company and patients suffering from IBS, positioning the company for commercial growth in 2026 and beyond [4] Market Need - Irritable bowel syndrome (IBS) affects about 10% to 15% of adults in the U.S., translating to over 30 million potential patients, highlighting a significant unmet medical need [4] - Current treatment options for IBS often provide inconsistent relief and may involve side effects, with no FDA-approved drugs for the IBS-M subtype, which represents about one-third of the IBS market [4] Product Efficacy - The inFoods® IBS test utilizes a personalized diagnostic approach to identify food triggers for IBS symptoms, allowing for targeted dietary recommendations [5] - Clinical trials demonstrated that 59.6% of patients who eliminated identified trigger foods met the FDA-standard target for abdominal pain reduction, compared to 42.2% in the control group [6] - Notable efficacy was observed in difficult-to-treat populations, with 67.1% of IBS-C patients and 66% of IBS-M patients achieving FDA-target pain reduction [7] Strategic Positioning - The combination of clinical evidence, a dedicated PLA code, and a national CLFS price represents a pivotal moment for inFoods® IBS [8] - The company plans to work with Medicare Administrative Contractors to secure coverage for the inFoods® IBS test and leverage the established pricing to negotiate with private insurers [10] Value Proposition - The CMS pricing announcement enhances Biomerica's market opportunity by providing a differentiated offering, a large patient population, a personalized medicine approach, and platform potential for additional gastrointestinal conditions [11]

Core Viewpoint - Viewbix Inc. is set to acquire Quantum X Labs, which has developed a groundbreaking quantum computing technology that enhances clinical trial methodologies, potentially transforming the pharmaceutical and drug discovery markets [4][5]. Group 1: Acquisition Details - Viewbix has signed a definitive agreement to acquire up to 100% (and not less than 85%) of Quantum X Labs, which includes its expanding patent portfolio [5]. - The acquisition is expected to close within 90 days from December 15, 2025, pending due diligence and regulatory approvals [5]. Group 2: Technological Advancements - Quantum X Labs has filed a provisional patent for a technology that improves Markov Chain Monte Carlo methods using quantum computing, allowing for more efficient sampling from complex probability distributions [2]. - The new methodology aims to reveal hidden biological structures and dependencies in clinical data, enabling better identification of patient clusters and treatment responses with potentially fewer samples than traditional methods [3]. Group 3: Market Implications - The advancements from Quantum X Labs could convert underpowered clinical trial datasets into robust mechanistic evidence, enhancing the success rates of personalized medicine [4]. - As quantum computing technology matures, it positions Viewbix to capture significant value in the pharmaceutical sector by reducing trial costs and timelines [4].

Business Verticals & Strategic Initiatives - ProPhase Labs is pursuing near-term cash recovery of over $50 million from COVID-19 receivables through Crown Medical Collections [7, 11, 24, 26, 92] - BE-Smart, an esophageal cancer diagnostic test, targets a $7-14 billion market [8, 34] - Nebula Genomics possesses a 16-petabyte DNA dataset, equivalent to roughly 150 million ancestry SNP-based tests, spanning 130 countries [9, 62] - ProPhase Labs signed a Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories S A (ABL), with ABL potentially becoming the majority owner (~76%) [20, 23] BE-Smart Esophageal Cancer Diagnostic - BE-Smart achieved greater than a 95% technical success rate in a key validation study evaluating its performance with esophageal brush cytology samples [44, 93] - The change in the annual incidence of Esophageal Adenocarcinoma (EAC) was 766 67% higher in 2017 compared to 1973 [32] Nebula Genomics - Nebula Genomics' DNA Complete offers Whole Genome Sequencing (WGS) analyzing virtually 100% of an individual's DNA [63] - DNA Expand expands raw DNA data more than 50 times to over 35 million genetic variants [73] Financial Restructuring - ProPhase Labs sold Pharmaloz Manufacturing for $23 6 million [18] - The company is saving over $6 million per year by shutting down the genomics laboratory [18]

--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries-- BRISBANE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pacira Biosciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints using Big dat ...

Group 1 - The S&P SmallCap 600 and MidCap 400 have underperformed compared to the S&P 500 over the past five years, but opportunities for smaller companies are expected to increase as the market shifts focus [2] - Allspring anticipates a rebalancing in the market, with smaller companies and sector-specific players gaining investor attention as AI technology becomes more prevalent [2][3] - Advisors may need to reconsider their allocations as the S&P 500, while currently strong, may become easier to outperform by small and mid-cap stocks in the next phase of AI development [3] Group 2 - AI and technology will remain central themes in 2026, and managers underweight in tech may face significant challenges [4] - Beyond large tech firms, various sectors are expected to benefit from AI integration into business and daily life [4] - The healthcare sector, despite facing challenges such as rising costs and policy uncertainty, is seeing advancements due to AI, which could lead to improved valuations [6] Group 3 - Allspring identifies industrials and materials as key sectors to watch, particularly for their roles in constructing data centers, highlighting companies like Amrize and Gates Corporation [6] - The healthcare sector is experiencing downward pressure on valuations, but AI advancements in personalized medicine present new investment opportunities [5][6]

Technology uses real-world sleep data and machine learning to help people with sleep apnea start and stay on therapySAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Settings (PTCS), to be marketed as Smart Comfort. Smart Comfort is the first FDA-cleared AI-enabled medical ...

Core Insights - Interpace Biosciences reported third quarter 2025 net revenue of $8.8 million, a decrease of 29% from $12.3 million in the same quarter of 2024, but an increase of 22% from $7.3 million on a pro forma basis [5][12] - The company achieved income from continuing operations of $1.0 million, down from $1.8 million in the prior year quarter [3][5] - The third quarter marked the first full quarter as a thyroid-only diagnostics testing company, with record thyroid test volumes and revenue [2][4] Financial Performance - Q3 2025 cash collections totaled $10.0 million, compared to $11.2 million in the prior year quarter [5] - Gross profit percentage was 62%, compared to 64% in the prior year quarter [5] - Adjusted EBITDA for Q3 2025 was $1.3 million, down from $2.5 million in the prior year quarter [5][21] Operational Highlights - Thyroid test volume increased by 12% year-over-year, reaching record levels [4] - The average revenue per test increased by 5% due to reimbursement improvements [2] - The company focused on enhancing operational efficiency through AI and automation [2] Strategic Positioning - Interpace's unique combination testing platform, including ThyGeNEXT and ThyraMIRv2, supports physicians in making informed patient-management decisions [2][7] - The company is positioned as an emerging leader in personalized medicine, offering specialized services along the therapeutic value chain [6]

Core Insights - The collaboration between Oracle Health and Life Sciences and the Cancer Center Informatics Society (Ci4CC) aims to advance AI innovation in oncology care and research [1][2] - The partnership will focus on designing an EHR optimized for cancer care, integrating clinical and genomic data for personalized medicine, and pioneering AI-driven approaches for clinical trial innovation [2][3] Collaboration Details - The strategic collaboration combines Oracle's technology with Ci4CC's national network of NCI-Designated and Community Care Cancer Centers [2] - The initiative will include establishing robust real-world evidence frameworks and advancing precision oncology platforms [2][4] Leadership Statements - Seema Verma from Oracle emphasized the potential of AI and data science in combating cancer, highlighting the opportunity to accelerate discoveries [2] - Sorena Nadaf-Rahrov from Ci4CC noted that advancements in cancer research require collaborative networks, which is central to their mission [3][4] Operational Goals - The collaboration aims to turn data into actionable knowledge to improve cancer research and patient care [4] - The agreement is non-binding, indicating a flexible approach to the partnership [4]